Last edition
News about
IMU Biosciences Partners with Waters to Advance AI Immune Mapping Platform
IMU Biosciences has selected Waters to advance its Artificial Intelligence (AI)-powered immune mapping platform, accelerating early disease diagnosis, patient monitoring, and precision medicine development.
HARNESS-1 study evaluates RC220 with osimertinib to address treatment resistance in EGFR-mutant non-small cell lung cancer, with the first patient showing no adverse events after initial dosing.
US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).
Merck KGaA Acquires Bio-Techne to Expand Life Sciences Business
Merck KGaA will acquire Bio-Techne in a USD 11.3 billion deal, strengthening its leadership in life sciences and expanding capabilities across high-growth markets.
Biocon Expands Diabetes Care in Malaysia as Duopharma Wins Insulin Tenders
Biocon strengthens diabetes care in Malaysia as Duopharma Biotech secures insulin tenders worth over MYR 225 million for human insulin, insulin glargine, and insulin aspart.
Shilpa Biologicals Commissions ADC Drug Substance GMP Facility in India
Shilpa Biologicals has launched an integrated Antibody Drug Conjugate (ADC) drug substance GMP facility in India, expanding Shilpa Medicare’s 25+ years of expertise in highly potent compound manufacturing.
The Union Health Ministry has expanded its QR code-based drug traceability framework to include vaccines, antimicrobials, NDPS medicines, and anti-cancer drugs, strengthening authentication and supply chain transparency.
Advanta bioKEMIX Forms Joint Venture with Resolkem to Expand High-Purity Solvent Manufacturing
Resolkem aims to combine advanced manufacturing capabilities with global market access to strengthen supply chains for pharmaceutical, biotechnology and specialty chemical industries.
Hikma Welcomes FDA Approval of Guardant360 Liquid CDx, Expanding Precision Cancer Diagnostics
The FDA-approved Guardant360 Liquid CDx enables advanced cancer biomarker testing through a simple blood draw, supporting faster and more precise treatment decisions.
The European Commission has approved Padcev in combination with Keytruda as the first perioperative treatment for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer in Europe.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy